TransEnterix, Inc. (TRXC) News
Filter TRXC News Items
TRXC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TRXC News Highlights
- TRXC's 30 day story count now stands at 19.
- Over the past 22 days, the trend for TRXC's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about TRXC are ASC, CE and ATNF.
Latest TRXC News From Around the Web
Below are the latest news stories about Transenterix Inc that investors may wish to consider to help them evaluate TRXC as an investment opportunity.
Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2020 Financial and Operating Results Conference Call for March 11, 2021Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release fourth quarter and fiscal year 2020 financial and operating results after the market closes on Thursday, March 11, 2021. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. |
Asensus Surgical Announces FDA Clearance in General SurgeryAsensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States. |
TransEnterix (TRXC) Flat As Market Gains: What You Should KnowTransEnterix (TRXC) closed at $3.72 in the latest trading session, marking no change from the prior day. |
Asensus Surgical to Present at the H.C. Wainwright Virtual Global Life Sciences ConferenceAsensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Global Life Sciences Conference taking place March 9 and March 10, 2021. |
Is TransEnterix a Good Stock to Buy Now?Shares of the robotic surgical-system manufacturer are soaring, but can this company become the next Intuitive Surgical? |
TransEnterix Announces Name Change to Asensus Surgical and Introduces a New Category of Surgery, Performance-Guided SurgeryTransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will change its corporate name to Asensus Surgical, Inc. The name change reflects the company's broader vision of shaping the future of surgery by integrating computer vision and machine learning with surgical robotics. While the company name change is effective today, the company's stock will begin trading under the new ticker symbol, NYSE American: ASXC, and name, Asensus Surgical, Inc., at the open of trading on March 5, 2021. |
Make a Surgical Strike with TransEnterix StockAs TRXC stock takes a breather amid a sustained uptrend, investors should consider owning shares of this medical robotics innovator. |
Vaccinex, Evolus leads healthcare gainers; China SXT Pharmaceuticals, Motus GI among major losersGainers: Vaccinex VCNX +148%, Evolus EOLS +60%, TransEnterix (TRXC) +17%, BioVie (BIVI) +16%, Auris Medical (EARS) +13%.Losers: China SXT Pharmaceuticals SXTC -21%, Motus GI MOTS -16%, 180 Life Sciences ATNF -11%, Lucira Health (LHDX) -10%, Onconova Therapeutics ONTX -10%.... |
TransEnterix Has A Compelling Case To Be The Next Intuitive SurgicalMedical devices company, TransEnterix (NYSEARCA:TRXC) is another small-cap growth stock that has sprung back to life in 2020. TRXC stock is up a whopping 1322% in the past six months. The company’s robotics platform will likely get significant traction this year, as regulatory approvals will support growth opportunities. The goal is for its “Senhance” robotics technology to gain widespread clinical adoption in the laparoscopic field. A few risks remain, though, and its inflated price limits TRXC stock’s attractiveness. Source: Shutterstock TransEnterix’s Senhance platform essentially reduces variability in surgical procedures and thus improves patient outcomes for laparoscopic procedures. The platform’s initial sales were encouraging but quickly dropped off, as it failed to meet physici... |
TransEnterix Announces New Training Center in EURESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the Company has agreed to partner with the Amsterdam Skills Centre (ASC) in the Netherlands for surgical training. This site will serve surgeons and staff throughout Europe with basic and advanced training on the Senhance® Surgical System. The ASC will also prov |